Cabazitaxel Patent Expiration
Cabazitaxel is used for treating metastatic castration-resistant prostate cancer after prior treatment with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone. It was first introduced by Sanofi Aventis Us Inc
Cabazitaxel Patents
Given below is the list of patents protecting Cabazitaxel, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jevtana Kit | US10583110 | Antitumoral use of cabazitaxel | Oct 27, 2030 | Sanofi Aventis Us |
| Jevtana Kit | US10716777 | Antitumoral use of cabazitaxel | Oct 27, 2030 | Sanofi Aventis Us |
| Jevtana Kit | US5438072 | Taxoid-based compositions |
Nov 22, 2013
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US5698582 | Compositions containing taxane derivatives |
Jul 03, 2012
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US5847170 | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit |
US5847170 (Pediatric) | Taxoids, their preparation and pharmaceutical compositions containing them |
Sep 26, 2021
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US6331635 | Taxoids, their preparation and pharmaceutical compositions containing them |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US6372780 | Methods of treating cell lines expressing multidrug resistance P-glycoprotein |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US6387946 | Methods for treating pathological conditions of abnormal cell proliferation |
Mar 26, 2016
(Expired) | Sanofi Aventis Us |
| Jevtana Kit | US7241907 | Acetone solvate of dimethoxy docetaxel and its process of preparation | Dec 10, 2025 | Sanofi Aventis Us |
| Jevtana Kit |
US7241907 (Pediatric) | Acetone solvate of dimethoxy docetaxel and its process of preparation | Jun 10, 2026 | Sanofi Aventis Us |
| Jevtana Kit | US8927592 | Antitumoral use of cabazitaxel | Oct 27, 2030 | Sanofi Aventis Us |
| Jevtana Kit |
US8927592 (Pediatric) | Antitumoral use of cabazitaxel | Apr 27, 2031 | Sanofi Aventis Us |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Cabazitaxel Generics
Several generic applications have been filed for Cabazitaxel. The first generic version for Cabazitaxel was by Breckenridge Pharmaceutical Inc and was approved on Jun 23, 2022. And the latest generic version is by Mylan Laboratories Ltd and was approved on Jul 5, 2023.
Given below is the list of companies who have filed for Cabazitaxel generic.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 1 generic for Cabazitaxel. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/1.5ML (40MG/ML) | solution | Prescription | INTRAVENOUS | AP | Oct 26, 2022 |
2. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Cabazitaxel. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/1.5ML (40MG/ML) | solution | Prescription | INTRAVENOUS | AP | Feb 10, 2023 |
3. MYLAN LABS LTD
Mylan Laboratories Ltd has filed for 1 generic for Cabazitaxel. Given below are the details of the strengths of this generic introduced by Mylan Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/1.5ML (40MG/ML) | solution | Discontinued | INTRAVENOUS | N/A | Jul 5, 2023 |
4. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 1 generic for Cabazitaxel. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/1.5ML (40MG/ML) | solution | Discontinued | INTRAVENOUS | N/A | Jun 23, 2022 |
5. APOTEX
Apotex Inc has filed for 1 generic for Cabazitaxel. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 60MG/1.5ML (40MG/ML) | solution | Discontinued | INTRAVENOUS | N/A | Feb 10, 2023 |